Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-22
2011-03-22
Bradley, Christina (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07910555
ABSTRACT:
The cell surface c-Met receptor, through which hepatocyte growth factor (HGF) signals are mediated, has now been identified as the Angiotensin-IV receptor (AT(4)R) in processes that include HGF-regulated cell motility, angiogenesis cancer metastasis and others. Disclosed are angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat conditions associated with c-Met dysregulation, including altering hepatocyte growth factor activity or c-Met receptor activity by administering an angiotensin-like factor that specifically binds to a cell surface c-Met receptor.
REFERENCES:
patent: 3920627 (1975-11-01), Wissmann et al.
patent: 5219883 (1993-06-01), Koszyk et al.
patent: 5227158 (1993-07-01), Jardieu
patent: 5296354 (1994-03-01), Simon et al.
patent: 5316921 (1994-05-01), Godowski et al.
patent: 5328837 (1994-07-01), Godowski
patent: 5464821 (1995-11-01), Stig et al.
patent: 5470753 (1995-11-01), Sepetov et al.
patent: 5854388 (1998-12-01), Harding et al.
patent: 6022696 (2000-02-01), Harding et al.
patent: 6294350 (2001-09-01), Peterson
patent: 6566098 (2003-05-01), Chan et al.
patent: 6641811 (2003-11-01), Suthanthiran et al.
patent: 6852316 (2005-02-01), Vinson et al.
patent: 7118747 (2006-10-01), Harding et al.
patent: 7375073 (2008-05-01), Tallant et al.
patent: 2005/0020519 (2005-01-01), Albiston et al.
patent: 2005/0222044 (2005-10-01), Harding et al.
patent: 2006/0128630 (2006-06-01), Harding et al.
patent: 2008/0008701 (2008-01-01), Harding et al.
patent: 2008/0194490 (2008-08-01), Harding et al.
patent: 0445606 (1991-11-01), None
patent: 9400492 (1994-01-01), None
patent: 0144270 (2001-06-01), None
patent: 0202593 (2002-01-01), None
patent: 03011304 (2003-02-01), None
patent: 2004078778 (2004-09-01), None
patent: 2008005531 (2008-01-01), None
patent: 2008005531 (2008-10-01), None
U.S. Appl. No. 60/819,201, filed Jul. 7, 2006, Harding et al.
Abhold, R.H. et al., “Metabolism of Angiotensins II and III by Membrane-Bound Peptidases from Rat Brain,” J. Pharmacol Exp. Ther. 245:171-177, 1988.
Albiston et al.,“Evidence That the Angiotensin IV (AT4) Receptor Is the Enzyme Insulin-regulated Aminopeptidase,” J. Biol. Chem., vol. 276, Issue 52, 48623-48626, Dec. 28, 2001.
Baker, K.M. et al., “Angiotensin II Stimulation of Protein Synthesis and Cell Growth in Chick Heart Cells.” Am. J. Physiol. 259(2):H610-H618, Aug. 1990.
Baker, K.M. et al., “Renin-Angiotensin System Involvement in Pressure-Overload Cardiac Hypertrophy in Rats,” Am. J. Physiol. 259(2):H324-H332, Aug. 1990.
Bell, L., et al., “Adipose tissue production of hepatocyte growth factor contributes to elevated serum HGF in obesity,” Am J Physiol Endocrinol Metab 291: E843-E848, Jun. 6, 2006.
Bennett, J.P. et al., “Receptor Binding Interactions of the Angiotensin II Antagonist, .sup.125 I-[Sarcosine.sup.1,Leucine.sup.8 ] Angiotensin II, With Mammalian Brain and Peripheral Tissues,” Eur. J. Pharmacol. 67(1):11-25, Oct. 3, 1980.
Berdichevsky et al., “Branching morphogenesis of human mammary epithelial cells in collagen gels,” Journal of Cell Science, 107(12) 3557-3568, 1994.
Birchmeier et al., “Met, Metastasis, Motility and More,” Nat. Rev. Mol. Cell Biol. 4:915, Dec. 2003.
Blair-West, J.R. et al., “Effect of the Heptapeptide (2-8) and Hexapeptide (3-8) Fragments Angiotensin II on Aldosterone Secretion,” J. Clin. Endocrinol. Metab. 32:575-578, 1971.
Blumberg, A.L., et al., “Angiotensin (A I, A II, A III) receptor characterization. Correlation of prostaglandin release with peptide degradation,” Circulation Research 41:154-158, Aug. 1977.
Bråkenhielm E., et al. “Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice,” Circ Res. 94(12):1579-88, Jun. 25, 2004.
Braszko, J.J. et al., “Angiotensin II-(3-8)-Hexapeptide Affects Motor Activity, Performance of Passive Avoidance and a Conditioned Avoidance Response in Rats,” Neurosci. 27(3):777-783, 1988.
Braszko, J.J. et al., “Psychotropic Effects of Angiotensin II and III in Rats: Locomotor and Exploratory vs. Cognitive Behavior,” Behav. Brain Res. 25:195-203, 1987.
Braszko, J.J. et al., “The 3-7 Fragment of Angiotensin II is Probably Responsible For its Psychoactive Properties,” Brain Res. 542(1):49-54, Feb. 22, 1991.
Bumpus, F.M. et al., “The Relationship of Structure to Pressor and Oxytocic Actions of Isoleucine.sup.5 Angiotensin Octapeptide and Various Analogues,” Biochim. Biophys. Acta 46:38-44, 1961.
Chai et al., “The Angiotensin IV/AT4 Receptor,” Cell. Mol. Life Sci. 61:2728-2737, 2004.
Chirgadze et al., “Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding,” Nature Struct. Biol. 6(1):72, Jan. 1999.
Christensen et al., “c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention,” Cancer Lett. 225:1-26, 2005.
Davis et al., “AT4 receptor activation increases intracellular calcium influx and induces a non-N-methyl-d-aspartate dependent form of long-term potentiation ,” 137(4): 1369-1379, 2006.
Donate, et al., “Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGFI/MSP),” Protein Science, 3(12) 2378-2394, 1994.
Esteban et al., “Angiotensin IV Activates the Nuclear Transcription Factor-B and Related Proinflammatory Genes in Vascular Smooth Muscle Cells,” Circ. Res. 96:965, May 2005.
Ferraro, et al., “Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS),” Oncogene. 25(26): 3689-369, Feb. 6, 2006.
Fitzsimons, J.T., “The Effect on Drinking of Peptide Precursors and of Shorter Chain Peptide Fragments of Angiotensin II Injected into the Rat's Diencephalon,” J. Physiol. Lond. 214:295, 1971.
Furge et al., “Met receptor tyrosine kinase: enhanced signaling through adapter proteins,” Oncogene 19, 5582-5589, Nov. 20, 2000.
Gherardi et al., “Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor ,” Proc. Nat. Acad. Sci. USA 100(21):12039-12044, Oct. 14, 2003.
Gherardi et al., “Structural basis of hepatocyte growth factor/scatter factor and MET signalling ,” Proc. Nat. Acad. Sci. USA 103(11):4046, Mar. 6, 2006.
Haberl, R.L. et al., “Angiotensin Degradation Products Mediate Endothelium-Dependent Dilation of Rabbit Brain Arterioles,” Circ. Res. 68:1621-1627, 1991.
Hanesworth et al., “Elucidation of a specific binding site for angiotensin II(3-8), angiotensin IV, in mammalian heart membranes.,” J. Pharmacol. Exp. Ther. 266(2): 1036-1042, Aug. 1993.
Amicone et al., “Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes,” EMBO J. 16: 495-503, 1997.
Harding et al., “AT4 receptors: Specificity and distribution,” Kidney Int. 46:1510-1512, 1994.
Harding, J.W. et al., “Angiotensin-Sensitive Neurons in the Rat Paraventricular Nucleus: Relative Potencies of Angiotensin II and Angiogensin III,” Brain Res. 410:130-134, 1987.
Hausman et al., “Adipose tissue angiogenesis,” Journal of animal science, 82(3): 925-934, 2004.
Higuchi et al., “Identification and Change in the Receptor for Hepatocyte Growth Factor in Rat Liver After Partial Hepatectomy of Induced Hepatitis,” Biochem. Biophys. Res. Commun. 176: 599-607, Apr. 30, 1991.
Jakubczak, et al., “NK1, a Natural Splice Variant of Hepatocyte Growth Factor/Scatter Factor, Is a Partial Agonist In Vivo,” Mol Cell Biol,18(3):1275-1283, Mar. 1998.
Jeffers et al., “Hepatocyte growth factor/scatter factor—Met signaling in tumorigenicity and invasion/metastasis ,” J. Mol. Med., 74(9): 505-513, Sep.
Elias Patrick D.
Harding Joseph W.
Wright John W.
Yamamoto Brent J.
Bradley Christina
Seed Intellectual Property Law Group PLLC
Washington State University Research Foundation
LandOfFree
C-Met receptor regulation by angiotensin IV (AT 4 )... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C-Met receptor regulation by angiotensin IV (AT 4 )..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C-Met receptor regulation by angiotensin IV (AT 4 )... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2760839